Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can)
- PMID: 23149498
- DOI: 10.1007/s10552-012-0096-6
Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can)
Abstract
Purpose: Little is known about the association between the metabolic syndrome (MetS) and the risk of gastric adenocarcinoma. The aim of this study was to investigate whether metabolic risk factors, together or combined, were associated with the risk of gastric adenocarcinoma.
Methods: The Metabolic Syndrome and Cancer Project (Me-Can) is a pooling of prospective cohorts in Austria, Norway, and Sweden with information on blood pressure, lipids, glucose, and BMI available in 578,700 individuals. Cox proportional hazards analysis was used to calculate hazard ratio (HR) of gastric adenocarcinoma using metabolic risk factors categorized into quintiles and transformed into z-scores (with mean = 0 and SD = 1). The standardized sum of all z-scores created a composite MetS score.
Results: In total, 1,210 incident cases of gastric adenocarcinoma were identified. Glucose was significantly associated with the risk of gastric adenocarcinoma [calibrated HR 1.58 (1.14-2.20) per one unit increment in z-score] in women. There was a statistically significant association between triglycerides and risk of gastric adenocarcinoma per mmol increment in triglycerides [HR 1.20 (1.06-1.36) per mmol] but not for the adjusted z-score in women. There were no significant association between any metabolic factors and gastric cancer among men. The composite MetS score was associated with the risk of gastric adenocarcinoma in women [HR 1.18 (1.00-1.38) per one unit increment in z-score] but not in men.
Conclusions: Glucose and high levels of the composite MetS score were associated with an increased risk of gastric adenocarcinoma in women but not in men.
Similar articles
-
Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project.Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1737-45. doi: 10.1158/1055-9965.EPI-10-0230. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20615887
-
Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can).Gynecol Oncol. 2012 May;125(2):330-5. doi: 10.1016/j.ygyno.2012.01.052. Epub 2012 Feb 10. Gynecol Oncol. 2012. PMID: 22330614
-
Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can).Br J Dermatol. 2012 Jul;167(1):59-67. doi: 10.1111/j.1365-2133.2012.10974.x. Epub 2012 Apr 24. Br J Dermatol. 2012. PMID: 22530854
-
Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can).Int J Cancer. 2011 Apr 15;128(8):1890-8. doi: 10.1002/ijc.25521. Int J Cancer. 2011. PMID: 20568111
-
Metabolic syndrome and gastric cancer risk: a systematic review and meta-analysis.Eur J Cancer Prev. 2021 May 1;30(3):239-250. doi: 10.1097/CEJ.0000000000000618. Eur J Cancer Prev. 2021. PMID: 32694278
Cited by
-
The Association Between Metabolic Syndrome and Gastric Cancer in Chinese.Front Oncol. 2018 Aug 23;8:326. doi: 10.3389/fonc.2018.00326. eCollection 2018. Front Oncol. 2018. PMID: 30191141 Free PMC article.
-
Metabolic syndrome and renal cell carcinoma.World J Surg Oncol. 2014 Jul 29;12:236. doi: 10.1186/1477-7819-12-236. World J Surg Oncol. 2014. PMID: 25069390 Free PMC article. Review.
-
Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study.EBioMedicine. 2017 Feb;15:73-80. doi: 10.1016/j.ebiom.2016.12.004. Epub 2016 Dec 7. EBioMedicine. 2017. PMID: 27979733 Free PMC article.
-
The fasting blood glucose and long non-coding RNA SNHG8 predict poor prognosis in patients with gastric carcinoma after radical gastrectomy.Aging (Albany NY). 2018 Oct 6;10(10):2646-2656. doi: 10.18632/aging.101576. Aging (Albany NY). 2018. PMID: 30299268 Free PMC article.
-
Prediction of three lipid derivatives for postoperative gastric cancer mortality: the Fujian prospective investigation of cancer (FIESTA) study.BMC Cancer. 2018 Aug 6;18(1):785. doi: 10.1186/s12885-018-4596-y. BMC Cancer. 2018. PMID: 30081869 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical